Analyzing the dynamics of meningococcal vaccinations initiatives by local government units in Poland (2017-2021) - Scope, challenges and recommendations.

Vaccine

Department of Health Economics and Medical Law, Faculty of Health Sciences, Medical University of Warsaw, 01-445 Warsaw, Poland; School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland. Electronic address:

Published: May 2024

Introduction: Meningococcal vaccinations are recommended by Polish public health authorities but lack coverage under health insurance, prompting Local Government Units (LGUs) to implement local health policy programs. This study examines the effectiveness and impact of LGU-driven meningococcal vaccination initiatives in Poland between 2017 and 2021.

Material And Methods: A retrospective analysis utilized data from reports on local public health interventions submitted annually to the Ministry of Health in Poland. The study focused on the number of meningococcal vaccination programs, their scope, the vaccinated population, and associated program costs. Additionally, nationwide data on meningococcal disease incidence and vaccine uptake were analyzed.

Results: Within LGUs programs, 48,617 individuals received meningococcal vaccinations, constituting approximately 10% of all vaccinations in Poland during the study period. Notably, cities with poviat rights spearheaded programs covering 54% of the total participants. The total cost incurred by these initiatives amounted to EUR 2,553,661.

Conclusions: While LGUs activities positively contributed to increased meningococcal vaccination rates, the overall engagement of local governments remains limited. The findings underscore the importance of expanding local government involvement in meningococcal vaccination programs to address public health needs effectively. Improved collaboration and increased funding may enhance the reach and impact of these initiatives.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2024.04.046DOI Listing

Publication Analysis

Top Keywords

meningococcal vaccination
16
meningococcal vaccinations
12
local government
12
public health
12
meningococcal
8
government units
8
poland study
8
vaccination programs
8
local
6
health
6

Similar Publications

IgA1 protease is one of the virulence factors of , and other pathogens causing bacterial meningitis. The aim of this research is to create recombinant proteins based on fragments of the mature IgA1 protease A-P from serogroup B strain H44/76. These proteins are potential components of an antimeningococcal vaccine for protection against infections caused by pathogenic strains of and other bacteria producing serine-type IgA1 proteases.

View Article and Find Full Text PDF

Background: This study aims to evaluate parents' knowledge about vaccination targeted for adolescents.

Methods: The cross-sectional survey was conducted between February and April 2024 in a sample of parents of adolescents attending middle and high schools in Southern Italy.

Results: Only 10.

View Article and Find Full Text PDF

Characterization of Unusual Serogroups of .

Microorganisms

December 2024

Institut Pasteur, Invasive Bacterial Infections, Université Paris Cité, 75015 Paris, France.

Most cases of invasive meningococcal disease (IMD) in Europe are caused by isolates of the serogroups B, C, W, and Y. We aimed to explore cases caused by other unusual serogroups. We retrospectively screened IMD cases in the databases of the National Reference Center for Meningococci and in France between 2014 and 2023.

View Article and Find Full Text PDF

The genus Neisseria includes two major human pathogens: N. meningitidis causing bacterial meningitis/septicemia and N. gonorrhoeae causing gonorrhoea.

View Article and Find Full Text PDF

In seropositive myasthenia gravis (MG), complement inhibition has been shown to be an effective and a fast-acting therapeutic option. Myasthenic crisis (MC), usually preceded by impending MC, is a life-threatening complication requiring highly effective treatments with rapid onset of action. Currently used treatment options of MC are limited, consisting mainly of symptomatic and immune therapies, that is, intravenous immunoglobulins and plasma exchange/immunoadsorption.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!